This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
The EURIPID collaboration is currently funded by an annual contribution fee of the participants and – for defined tasks and deliverables – a grant of the EU.
This website is part of the project ’826652 Euripid’ which is co-funded by the European Union’s Health Programme (2014-2020).
The content of this website represents the views of the author only and is his/her sole responsibility; it cannot be considered to reflect the views of the European Commission and/or the Consumers, Health, Agriculture and Food Executive Agency (CHAFEA) or any other body of the European Union. The European Commission and the Agency do not accept any responsibility for use that may be made of the information it contains.
Pharmaceutical pricing webinar January
/in News /by Bettina HeindlThe first basic webinar in the new series on pharmaceutical pricing organised by the Euripid collaboration took place on 28 January 2022 and was, with more than 150 registered participants, a huge success. After an introduction by the Chair of the Board of Participants, Francis Aricks (RIZIV/INAMI, Belgium), the project coordinator Gergely Németh (NEAK, Hungary) […]
Members‘ Meeting September 2022
/in News /by Bettina HeindlWe would like to announce that the BoP meeting took place on 21st September 2021. DG SANTE presented insights of the European Pharma Strategy, AIFA gave an overview of the publication „Medicine price transparency and confidential managed-entry agreements in Europe: findings from the EURIPID survey. In: Health Policy, 125;9 (2021)“ and the Austrian National Public […]
Enlargement of the database
/in News /by Janos MuzsiIt is considered to expand the database and for this purpose there was a survey among the members about the priority of the possible additional information suche as Volume information, MEA, further price regulated products or Medical devices should and can be included in the database. The survey is still ongoing.